The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38744632.
- Also identified by DOI 10.1016/j.eururo.2024.04.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Large trials of immune checkpoint inhibitors (ICIs) in castration-resistant prostate cancer (CRPC) have mostly failed. Biomarker-selected CRPC patients, especially those with high microsatellite instability (MSI-H), mismatch repair deficiency (dMMR), or elevated tumor mutational burden (TMB), may benefit from single-agent ICIs. Despite their rarity in CRPC (∼2-5%), identification of MSI-H, dMMR, or TMB-H could improve patient selection for immunotherapy.
Medical subject headings
- Biomarkers, Tumor
- DNA Mismatch Repair
- Immunotherapy
- Microsatellite Instability
- Mutation
- Prostatic Neoplasms, Castration-Resistant